Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
About Us
Careers
Conferences
Videos
Webinars
Press Releases
Whitepapers
Advertising
Top Story
FDA Clearance
Pillar Biosciences gets FDA approval for NGS solid tumor profiling test
Pillar Biosciences has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its OncoReveal CDx pan-cancer next-generation sequencing (NGS) test for general solid tumor profiling.
Featured
Validation
Immunovia announces positive results for next-gen pancreatic cancer test
Collaboration
Vertex to pay $25M upfront to scale cell manufacturing technology
Latest News
Labcorp buys Invitae portfolio for $239M
April 26, 2024
Sponsored
Visit our Molecular Diagnostics Community
April 5, 2024
U.K. Patents Court rules Bio-Techne patents invalid in infringement lawsuit
April 24, 2024
Scout secures CARB-X grant to advance diagnostic test development
April 22, 2024
Business Insights
FDA Clearance
Pillar Biosciences gets FDA approval for NGS solid tumor profiling test
Collaboration
Vertex to pay $25M upfront to scale cell manufacturing technology
Mergers & Acquisitions
Labcorp buys Invitae portfolio for $239M
Financial Results
Bristol Myers Squibb to reduce workforce in restructuring plan
Diagnostic Technologies
Sequencing
Mission Bio launches new features for Tapestri platform
Gene silencing and gene editing
Engineered Cas clears barrier to antiviral CRISPR therapies
Artificial Intelligence
AI-powered endoscope doubles detection of high-risk esophageal lesions
Diagnostic Technologies
Veracyte to share bundle of genomic classifier studies at AUA 2024
Diseases
Validation
Immunovia announces positive results for next-gen pancreatic cancer test
Collaboration
Vertex to pay $25M upfront to scale cell manufacturing technology
Point-of-Care Testing
Scout secures CARB-X grant to advance diagnostic test development
Alzheimer's
Quest adds new biomarker test to Alzheimer's portfolio
More from LabPulse.com
Molecular diagnostic test study continues EET benefit assessment
By
Liz Carey
A molecular oncology gene expression profiling (GEP) test for breast cancer biomarkers may influence extended endocrine therapy (EET) treatment decisions, according to an impact study.
April 2, 2024
Magritek enhances benchtop NMR instruments
By
LabPulse.com staff writers
Nuclear magnetic resonance software builds capabilities for labs looking for synthetic drugs and new psychoactive substances, using benchtop NMR instruments.
March 29, 2024
Florida man pleads guilty in $4.6 million kickback scheme
By
LabPulse.com staff writers
A Tampa, FL man pleaded guilty for his role in a scheme to receive kickbacks and bribes from labs in exchange for referrals of patient DNA samples and genetic tests, according to the U.S. Attorney's Office for the District of New Jersey.
March 29, 2024
BioMĂ©rieux gets FDA 510(k) clearance, CLIA waiver approval for panel
By
LabPulse.com staff writers
BioMĂ©rieux's Biofire Spotfire Respiratory/Sore Throat Panel has received dual FDA 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver approval.
March 27, 2024
Labcorp acquires BioReference Health assets
By
LabPulse.com staff writers
Labcorp and Opko Health subsidiary BioReference Health have announced that they have made an agreement for Labcorp to acquire certain of BioReference Health’s assets.
March 28, 2024
Castle Biosciences shares melanoma test study data at SSO 2024
By
LabPulse.com staff writers
Castle Biosciences shared data from two studies on the performance of its DecisionDx-Melanoma test in patients with cutaneous melanoma at the Society of Surgical Oncology 2024 (SSO 2024) annual meeting, held March 20-23 in Atlanta.
March 26, 2024
Ibex presents new study data for AI-powered cancer diagnostics platform
By
Matt Limb
Ibex Medical Analytics is hailing positive data from studies with U.S. partners on the impact of its artificial intelligence (AI)-powered cancer diagnostic platform Galen.
March 26, 2024
Eventually, an oral cancer diagnosis may be a lick away
By
Melissa Busch
The University of Birmingham in the U.K. will develop a new, noninvasive way to diagnose mouth cancer that has a sweet twist.
March 28, 2024
AbbVie to buy Landos Biopharma for up to $212M
By
LabPulse.com staff writers
AbbVie has announced that it will buy drug developer Landos Biopharma in a deal worth up to $212 million. The deal will expand Abbvie’s portfolio, especially in the arena of immune system-related illnesses.
March 25, 2024
Study sheds light on the organization of immune cells in tumors
By
Matt Limb
Researchers have revealed how immune cells are spatially organized within some tumors and that certain immune “hubs” may be linked to better cancer treatment responses.
March 27, 2024
Bio-Techne receives IVDR certification for chronic myeloid leukemia monitoring test
By
LabPulse.com staff writers
Bio-Techne has announced that Asuragen, part of its molecular diagnostics division, has completed class C certification under the new European Union IVDR for its QuantideX qPCR BCR-ABL IS kit for monitoring chronic myeloid leukemia.
March 22, 2024
Protein design firm Profluent raises $35M in funding
By
LabPulse.com staff writers
Protein design firm Profluent has raised $35 million in funding, bringing the total funding raised by the company to $44 million.
March 25, 2024